NUCIEN PHARMA(SH:688189)2023-10-30 16:00Financial Performance - The company's revenue for the third quarter was ¥48,309,175.65, a decrease of 67.15% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥27,757,679.02, with a year-to-date net profit of ¥650,517.07, reflecting a decline of 95.52%[5]. - The company reported a basic earnings per share of -¥0.1012 for the quarter, a decrease of 95.52% year-to-date[6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥28,665,688.55 for the quarter, with a year-to-date figure of ¥5,863,681.98, down by 31.12%[5]. - The net profit for the first three quarters of 2023 was CNY 998,459.62, a significant decline from CNY 3,723,876.14 in the previous year, reflecting challenges in profitability[20]. - The company reported a total profit of CNY -1,900,148.51 for the first three quarters of 2023, contrasting with a profit of CNY 6,083,796.26 in 2022, highlighting a significant downturn in financial performance[20]. Research and Development - Research and development (R&D) expenses totaled ¥17,045,021.46 for the quarter, representing an increase of 18.88%, and accounted for 35.28% of revenue, up by 25.53 percentage points[6]. - The company is currently conducting clinical trials for new projects, including hydrochloride mefloquine tablets and paracetamol inhalation solution, which has led to increased R&D investment[10]. - Research and development expenses increased to CNY 63,925,857.68 in 2023, up from CNY 38,936,841.28 in 2022, highlighting a focus on innovation[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,677,228,137.78, a decrease of 14.16% from the end of the previous year[6]. - Total current assets as of September 30, 2023, amount to ¥1,231,656,921.13, a decrease from ¥1,496,172,292.33 as of December 31, 2022[14]. - Total non-current assets as of September 30, 2023, are ¥445,571,216.65, down from ¥457,619,851.65 as of December 31, 2022[15]. - The company has a total asset of ¥1,677,228,137.78 as of September 30, 2023, compared to ¥1,953,792,143.98 as of December 31, 2022[15]. - The total liabilities decreased to CNY 379,858,009.80 in 2023 from CNY 657,420,475.62 in 2022, suggesting a reduction in financial leverage[19]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥88,584,510.48, indicating an increase compared to the previous year[5]. - Cash inflow from operating activities reached CNY 626,379,760.43 in the first three quarters of 2023, compared to CNY 406,204,343.61 in 2022, indicating improved cash generation[23]. - The net cash flow from operating activities was 88,584,510.48, compared to a negative cash flow of -149,920,202.51 in the previous period[24]. - Cash outflows from operating activities totaled 537,795,249.95, slightly down from 556,124,546.12[24]. - The ending balance of cash and cash equivalents was 501,891,678.69, down from 547,128,233.71[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,927[12]. - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, accounting for 28.57% of total shares[12]. - Basic earnings per share for the first three quarters of 2023 were CNY 0.0024, down from CNY 0.0529 in the same period of 2022, indicating a decline in shareholder returns[21]. Operational Insights - The company experienced a significant decline in sales prices of major products, contributing to the drop in revenue and net profit[10]. - The company has not reported any audited financial statements for the third quarter[4]. - The company has not disclosed any significant new strategies or product developments during the reporting period[14]. - Total operating revenue for the first three quarters of 2023 was CNY 547,468,507.21, a decrease of 2.5% compared to CNY 562,058,852.86 in the same period of 2022[19]. - Total operating costs for the first three quarters of 2023 were CNY 508,120,982.75, slightly down from CNY 509,161,609.51 in 2022, indicating a stable cost management strategy[19].